Last reviewed · How we verify
SSRIs
At a glance
| Generic name | SSRIs |
|---|---|
| Also known as | SSRIs antidepressants, Fluoxetine, Paroxetine, Fluvoxamine, Escitalopram |
| Sponsor | The Third Affiliated hospital of Zhejiang Chinese Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Electrophysiological Markers of Antidepressants in Major Depressive Disorder (NA)
- Intradermal Acupuncture for Assisting SSRI Dose Reduction in Major Depressive Disorder (NA)
- MODELING OBSESSIVE COMPULSIVE DISORDER AND EXPLORING TREATMENT RESPONSE USING INNOVATIVE THERAPIES AND STEM CELLS (NA)
- TDM-Guided Treatment With SSRIs in Hospitalized Adults and Children (PHASE4)
- Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease (PHASE2)
- Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms (PHASE3)
- A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)
- Effect of Virtual Reality on Depression in Adolescent Females (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SSRIs CI brief — competitive landscape report
- SSRIs updates RSS · CI watch RSS
- The Third Affiliated hospital of Zhejiang Chinese Medical University portfolio CI